secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001104659-25-099534
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea sets ATRN-119 RP2D at 1,100 mg QD; pauses monotherapy; prioritizes WEE1 inhibitor APR-1051
--------------------------------------------------------------------------------

- RP2D of 1,100 mg once daily identified for ATRN-119 from ABOYA-119 Phase 1/2a study.
- Further enrollment paused in both QD and BID monotherapy arms; currently-dosed patients continue without interruption.
- Considering combination with radiation (HPV+ head & neck), ADCs, and checkpoint inhibitors; discussions with academic centers.
- Lead WEE1 inhibitor APR-1051 advancing; Phase 1 data expected at AACR-NCI-EORTC conference on Oct 24, 2025.
- ATRN-119 showed durable disease stabilization, manageable AEs, dose-proportional PK at RP2D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925099534/0001104659-25-099534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925099534/apre-20251015x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-099534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer